$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Henry Schein posts strong Q2 revenue but faces margin pressures; strategic focus on specialty and technology segments aims to drive long-term growth despite near-term headwinds.

# Henry Schein Q2 FY2025: Revenue Resilience Amid Margin Pressures, Strategic Shift to High-Growth Segments

---

## Executive Summary

- **Henry Schein delivered Q2 FY2025 revenue of $3.24 billion, up 3.3% YoY, beating consensus on the top line**. However, both GAAP EPS ($0.70) and Non-GAAP EPS ($1.10) missed expectations and prior-year levels, reflecting ongoing margin compression.
- **Earnings quality was impacted by flat gross profit and a decline in operating income** (down to $151M from $159M YoY), as promotional activity and lower glove pricing weighed on margins, particularly in the U.S. dental distribution channel.
- **Management struck a cautiously defensive tone**, acknowledging near-term headwinds from restructuring and margin pressure, but reaffirmed full-year guidance and expressed confidence in a stronger second half, underpinned by cost-saving initiatives and a shift toward higher-margin specialty and technology segments.
- **Key risks include persistent margin headwinds, regulatory and cyber threats, and supply chain pressures**. However, the company’s ongoing restructuring and focus on high-growth, high-margin businesses—now accounting for over 45% of non-GAAP operating income—offer significant long-term upside.
- **Catalyst watch:** Investors should monitor the pace of cost savings realization, margin recovery in the dental segment, and progress in technology and specialty business growth as potential drivers for re-rating in H2 FY2025.

---

## Performance Snapshot

| Metric                | Reported      | Consensus   | Surprise      | YoY Change   |
|-----------------------|--------------|-------------|---------------|-------------|
| Revenue               | $3.24B       | $3.18B      | +$60M         | +3.3%       |
| GAAP EPS              | $0.70        | $0.78       | -$0.08        | -           |
| Non-GAAP EPS          | $1.10        | $1.18       | -$0.08        | -           |
| Operating Income      | $151M        | —           | —             | -5%         |
| Gross Profit          | Flat         | —           | —             | —           |
| Specialty/Tech Share* | >45% of OpInc| —           | —             | +           |

*Specialty and technology segments as a share of non-GAAP operating income.

---

## Earnings Quality

- **Revenue growth was volume-driven**, with core medical, specialty, and technology segments offsetting softness in the U.S. dental channel.
- **Gross profit was flat YoY**, while operating income declined, reflecting **margin pressure from promotional activity and lower pricing** (notably in gloves).
- **Restructuring and promotional costs increased**, with restructuring expenses rising to $23M (from $15M YoY), and ongoing investments in sales and operational consolidation.
- **Cost control measures are underway**, targeting over $100M in annual savings by 2026, but these benefits are expected to be back-end loaded.

---

## Management Commentary & Guidance

- **Management’s tone was cautiously defensive**, acknowledging short-term margin and cost headwinds but reiterating confidence in H2 recovery.
- **FY2025 guidance was maintained**: Non-GAAP EPS of $4.80–$4.94, sales growth of 2–4%, and mid-single digit adjusted EBITDA growth.
- **Assumptions include margin stabilization in H2**, successful execution of cost-saving initiatives, and continued growth in specialty and technology segments.

---

## Key Risks

- **Margin pressures** from competitive pricing, promotional discounting, and cost inflation, especially in the dental channel.
- **Regulatory and cyber risks** remain elevated following the recent cyber incident.
- **Supply chain volatility** could impact cost structure and inventory management.

---

## Expected Market Reaction

- **Short-term caution is likely**, as investors focus on the earnings miss and margin compression.
- **Analysts may highlight the company’s strategic shift and cost-saving potential**, but near-term sentiment could remain muted until margin recovery is evident.
- **Potential market mispricing**: The market may be overemphasizing current margin headwinds and underappreciating the long-term benefits of restructuring and business mix evolution.

---

## Final Takeaway

- **Henry Schein’s Q2 FY2025 was a mixed quarter**: strong revenue growth and strategic progress in high-margin segments, but profitability remains under pressure.
- **The market may be underestimating the long-term upside** from cost savings and the shift to specialty and technology, while overreacting to near-term margin challenges.
- **Upcoming catalysts**: (1) Margin recovery and cost savings realization in H2 FY2025; (2) Continued growth in specialty and technology segments; (3) Updates on regulatory and cyber risk mitigation.

---

Henry Schein: Margin Pressures, Specialty Shift in Focus

Henry Schein’s specialty and technology segments drive margin and EPS growth, while improved working capital management boosts cash flow resilience despite stable topline and macro risks.

# Henry Schein, Inc.: Specialty Momentum and Operational Discipline Set the Stage for a Resilient Quarter

## Executive Summary

We maintain a **Neutral-to-Bullish** outlook for Henry Schein, Inc. (NASDAQ: HSIC) heading into the upcoming quarter. Recent results highlight a **stable revenue base of $3.168B in Q1 FY2025**, with a notable shift toward higher-margin specialty and technology segments—these grew **+4.3% and +3.4% YoY (constant currency)**, respectively. Operating margin improved to **5.5%** (from 4.7% prior quarter), reflecting both segment mix and restructuring benefits. However, the market may be underestimating the **positive impact of improved working capital management**—notably, **DSO fell from 50.4 to 44.1 days**, which could support near-term EPS and cash flow. Risks remain from tariff/FX volatility and persistent working capital tightness, but the company’s operational discipline and segmental momentum provide a constructive setup for the next quarter.

## Recent Trends Signal What’s Next

Henry Schein’s last two quarters reveal a **stable topline with improving profitability**. While total revenue has plateaued, the mix is shifting toward higher-margin businesses. Gross margin saw slight pressure, declining from **31.9% to 31.6%**, but operating margin expanded from **4.7% to 5.5%** due to restructuring and segment mix. Specialty and technology segments are now the primary growth engines, offsetting flat or declining distribution revenues.

### Quarterly Financial Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------|
| Q2 FY2024    | 3.15         | 31.8             | 4.7                  | 1.21    |
| Q3 FY2024    | 3.17         | 31.9             | 5.0                  | 1.28    |
| Q4 FY2024    | 3.16         | 31.7             | 5.2                  | 1.30    |
| Q1 FY2025    | 3.168        | 31.6             | 5.5                  | 1.33    |

**Trend:** Revenue is stable, but operating margin and EPS are trending upward, driven by mix and cost actions.

## Management’s Forward Tone and Positioning

Management’s recent commentary is **cautiously optimistic**, emphasizing operational resilience and segmental momentum. In the Q1 2025 call, leadership stated, **“We’re seeing stable demand and good momentum in our specialty and technology businesses.”** This contrasts with the more defensive tone of prior quarters, where focus was on “navigating working capital headwinds.” The current guidance for **full-year sales growth of 2%–4% and non-GAAP EPS of $4.80–$4.94** signals confidence in the company’s ability to offset macro and cost pressures with internal execution and mix improvement.

## KPI Trends & Upcoming Quarter Drivers

Three KPIs are most relevant for the next quarter:

- **Days Sales Outstanding (DSO):** Improved from **50.4 to 44.1 days** QoQ, indicating better cash conversion and potential for improved liquidity.
- **Inventory Turnover:** Slightly declined from **4.9 to 4.8**, suggesting inventory management remains a focus area but is not yet a concern.
- **Specialty/Technology Segment Growth:** Specialty up **+4.3% YoY** and Technology up **+3.4% YoY** (constant currency), both outpacing the core distribution segment.

### KPI Movement Table

| KPI                    | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|------------------------|-----------|-----------|-----------|------------|------------|
| DSO (days)             | 50.4      | 48.2      | 44.1      | -6.3       | -4.1       |
| Inventory Turnover     | 4.9       | 4.8       | 4.8       | -0.1       | 0.0        |
| Specialty Growth (%)   | 3.8       | 4.1       | 4.3       | +0.5       | +0.2       |
| Technology Growth (%)  | 2.9       | 3.2       | 3.4       | +0.5       | +0.2       |

**Implication:** Improved DSO and segment growth support margin and EPS upside, while inventory turnover warrants monitoring.

## Missed by the Street

A key overlooked signal is the **rapid improvement in DSO (down 6.3 days YoY)**, which could drive a **faster-than-expected rebound in free cash flow**. While consensus is focused on revenue stagnation, the company’s ability to convert sales into cash is improving, as highlighted by management: **“We are seeing tangible benefits from our working capital initiatives.”** (Q1 2025 Call). This operational leverage may cushion EPS even if topline growth remains modest.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($B) | EPS (GAAP) | Operating Margin (%) | Key Assumptions                                                                 |
|----------|--------------|------------|----------------------|---------------------------------------------------------------------------------|
| Bull     | 3.20+        | 1.40–1.42  | ~6.0                 | Specialty/tech outperformance, further DSO gains, muted tariff/FX impact        |
| Base     | 3.17         | 1.33–1.38  | ~5.5                 | Stable demand, continued restructuring savings, manageable FX/tariff headwinds   |
| Bear     | 3.15-        | 1.25–1.30  | ~5.0                 | Distribution softness, adverse FX/tariffs, inventory/working capital setbacks    |

**Most Likely:** The **Base case** is most probable, given current demand stability, ongoing cost actions, and segmental momentum, but with persistent macro and working capital risks.

## Appendix – Data Tables & Management Quotes

### Quarterly Financials Table

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q2 FY2024    | 3.15         | 1.21    | 31.8             | 4.7                  |
| Q3 FY2024    | 3.17         | 1.28    | 31.9             | 5.0                  |
| Q4 FY2024    | 3.16         | 1.30    | 31.7             | 5.2                  |
| Q1 FY2025    | 3.168        | 1.33    | 31.6             | 5.5                  |

### KPI Movement Table

| KPI                    | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|------------------------|-----------|-----------|-----------|------------|------------|
| DSO (days)             | 50.4      | 48.2      | 44.1      | -6.3       | -4.1       |
| Inventory Turnover     | 4.9       | 4.8       | 4.8       | -0.1       | 0.0        |
| Specialty Growth (%)   | 3.8       | 4.1       | 4.3       | +0.5       | +0.2       |
| Technology Growth (%)  | 2.9       | 3.2       | 3.4       | +0.5       | +0.2       |

### Key Management Quotes

1. **“We’re seeing stable demand and good momentum in our specialty and technology businesses.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Underpins confidence in higher-margin segment growth.*

2. **“We are seeing tangible benefits from our working capital initiatives.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Signals improved cash flow and potential EPS support.*

3. **“Our restructuring program is on track to deliver $75M–$100M in annualized savings.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Margin expansion likely to continue near term.*

4. **“Tariff and FX headwinds remain a risk, but we are actively managing cost pass-through.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Margin risk if cost pass-through lags.*

5. **“Inventory levels are being closely monitored to align with demand.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Inventory turnover is a watchpoint for future quarters.*

6. **“We expect full-year sales growth of 2%–4% and non-GAAP EPS of $4.80–$4.94.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Sets a moderate but achievable bar for the next quarter.*

7. **“We continue to see softness in the distribution segment, but specialty and technology are offsetting this.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Mix shift is key to sustaining growth and margins.*

---

**Conclusion:**  
Henry Schein’s next quarter will be defined by its ability to capitalize on specialty and technology momentum, maintain operational discipline, and navigate external risks. The company’s improving working capital profile is a potential upside catalyst that the market may be underappreciating.

HSIC: Specialty Growth & Cash Flow Resilience